---
title: Modeling KRAS inhibitor drug tolerance and resistance with patient-derived organoids
description: Discover how our advanced drug exposure protocol enables the development of KRAS inhibitor-tolerant and resistant organoid clones. Download the poster to access detailed methods and exclusive insights into modeling resistance for drug discovery.
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

# Modeling KRAS inhibitor drug tolerance and resistance with patient-derived organoids

Discover how our advanced drug exposure protocol enables the development of KRAS inhibitor-tolerant and resistant organoid clones. Download the poster to access detailed methods and exclusive insights into modeling resistance for drug discovery.

**just released! 3 other researchers are viewing this** 

download now

## KRAS resistance in cancer treatment

![section-img2](https://resources.huborganoids.nl/hs-fs/hubfs/assets2024/icon-krystal-hcp.png?width=483&height=508&name=icon-krystal-hcp.png)

KRAS mutations drive some of the most aggressive cancers, but even the most promising therapies face a major hurdle: resistance. Tumor cells can survive treatment by entering a reversible “drug-tolerant persister” state, eventually acquiring permanent genetic changes that render therapy ineffective. Understanding this journey from persistence to resistance is critical for developing strategies that prevent treatment failure.

## Download the poster to discover:

- How HUB Organoids faithfully recapitulate patient tumors, making them ideal for studying resistance
- How we generated persistent and resistant PDO models using stepwise drug exposure and dose escalation
- Whole exome sequencing data revealing KRAS-pathway mutations unique to resistant models
- Transcriptomic profiles showing distinct resistant-specific expression patterns, including downregulation of drug transporter pumps

download poster

## Learn how our KRASmut organoid screen enables efficient testing of inhibitors and combination therapies

[download poster](https://resources.huborganoids.nl/-aacr-poster-2025-a-patient-derived-organoid-screening-platform-as-a-powerful-tool-to-study-efficacy-of-kras-inhibitors-krascampaign)

![section-img3](https://resources.huborganoids.nl/hs-fs/hubfs/assets2024/poster-thumb-efficacy-of-kras-inhibitors.png?width=600&name=poster-thumb-efficacy-of-kras-inhibitors.png)

×

### Download poster

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*